Ventyx Biosciences (VTYX) takeover deal with Eli Lilly (LLY) is reportedly being debated at USD 14/shr in cash; could be announced later today, according to the WSJ

Ventyx Biosciences (VTYX) takeover deal with Eli Lilly (LLY) is reportedly being debated at USD 14/shr in cash; could be announced later today, according to the WSJ.

The potential takeover of Ventyx Biosciences by Eli Lilly at $14 per share could indicate strategic consolidation in the pharmaceuticals sector, particularly in biotechnology. If confirmed, this deal might set a precedent for further M&A activity in the space, while boosting Eli Lilly's position in the market. Traders should monitor the stock reactions and implications for both companies, including any changes in valuation or competitive dynamics within the industry.